secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2021-11-02T23:59:59+00:00
Accession:  0001570562-21-000171
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q3 revenue $26.7M (+58% YoY); record sales; initiates extra-strength Jeuveau Phase II
--------------------------------------------------------------------------------

- U.S. net revenue of $26.7M, up 58% YoY; total net revenue up 51% to $26.7M.
- GAAP operating loss $19.1M vs. $8.8M YoY; non-GAAP operating loss $14.3M vs. $6.5M.
- Cash $107.8M at Sept 30, down from $131.7M due to $15M milestone payment.
- Initiated Phase II for extra-strength Jeuveau; first patient expected Q1 2022, completion 1H 2023.
- Accounts purchasing Jeuveau increased by 500 to >6,500; loyalty program doubled to 240,000 registrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056221000171/0001570562-21-000171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056221000171/eols-20211102.htm
  HTML page:      https://secwatch.observer/filing/0001570562-21-000171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer